Tibet Weixinkang Medicine Co Ltd (603676) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tibet Weixinkang Medicine Co Ltd (603676) has a cash flow conversion efficiency ratio of 0.009x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥13.68 Million ≈ $2.00 Million USD) by net assets (CN¥1.53 Billion ≈ $223.37 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Tibet Weixinkang Medicine Co Ltd - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Tibet Weixinkang Medicine Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 603676 liabilities breakdown for a breakdown of total debt and financial obligations.
Tibet Weixinkang Medicine Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tibet Weixinkang Medicine Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MorningStar Partners, L.P.
NYSE:TXO
|
0.038x |
|
Latham Group Inc
NASDAQ:SWIM
|
0.125x |
|
Lexicon Pharmaceuticals Inc
NASDAQ:LXRX
|
-0.160x |
|
AmRest Holdings SE
MC:EAT
|
0.278x |
|
Zhejiang Kanglongda Special
SHG:603665
|
0.024x |
|
MLP Group S.A.
WAR:MLG
|
0.012x |
|
Rongcheer Industrial Technology (Suzhou) Co. Ltd. A
SHE:301360
|
N/A |
|
Fidus Investment Corp
NASDAQ:FDUS
|
0.008x |
Annual Cash Flow Conversion Efficiency for Tibet Weixinkang Medicine Co Ltd (2013–2024)
The table below shows the annual cash flow conversion efficiency of Tibet Weixinkang Medicine Co Ltd from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see Tibet Weixinkang Medicine Co Ltd (603676) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.39 Billion ≈ $202.73 Million |
CN¥372.78 Million ≈ $54.55 Million |
0.269x | +40.51% |
| 2023-12-31 | CN¥1.34 Billion ≈ $196.13 Million |
CN¥256.67 Million ≈ $37.56 Million |
0.191x | -5.04% |
| 2022-12-31 | CN¥1.22 Billion ≈ $178.61 Million |
CN¥246.15 Million ≈ $36.02 Million |
0.202x | +26.10% |
| 2021-12-31 | CN¥1.07 Billion ≈ $156.17 Million |
CN¥170.69 Million ≈ $24.98 Million |
0.160x | +17.61% |
| 2020-12-31 | CN¥983.21 Million ≈ $143.87 Million |
CN¥133.70 Million ≈ $19.56 Million |
0.136x | +18.93% |
| 2019-12-31 | CN¥930.05 Million ≈ $136.10 Million |
CN¥106.34 Million ≈ $15.56 Million |
0.114x | +23.41% |
| 2018-12-31 | CN¥897.64 Million ≈ $131.35 Million |
CN¥83.17 Million ≈ $12.17 Million |
0.093x | +25.59% |
| 2017-12-31 | CN¥858.04 Million ≈ $125.56 Million |
CN¥63.30 Million ≈ $9.26 Million |
0.074x | -67.34% |
| 2016-12-31 | CN¥459.42 Million ≈ $67.23 Million |
CN¥103.79 Million ≈ $15.19 Million |
0.226x | -20.48% |
| 2015-12-31 | CN¥402.93 Million ≈ $58.96 Million |
CN¥114.47 Million ≈ $16.75 Million |
0.284x | -31.35% |
| 2014-12-31 | CN¥286.28 Million ≈ $41.89 Million |
CN¥118.47 Million ≈ $17.34 Million |
0.414x | +15.75% |
| 2013-12-31 | CN¥247.78 Million ≈ $36.26 Million |
CN¥88.59 Million ≈ $12.96 Million |
0.358x | -- |
About Tibet Weixinkang Medicine Co Ltd
Tibet Weixinkang Medicine Co., Ltd. engages in the research and development, production, and sale of chemical drugs and their bulk drugs in China. The company offers parenteral nutrition vitamins; electrolyte supplements; intravenous iron, trace, electrolytes, and amino acids supplements; antibiotics; acetylcysteine solution for inhalation; medicine for liver diseases; and other special fields. I… Read more